We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
MHRA updates product information regarding the very rare risk of non-arteritic anterior ischemic optic neuropathy (NAION) in patients taking semaglutide.
By Julia Vitarello
Updated product information for healthcare professionals and patients regarding the small risk of severe acute pancreatitis in patients taking GLP-1s.
Batches of quetiapine oral suspension from Eaststone Limited are being recalled due to the active content being twice the amount it should be. Patients should not stop taking this medicine without consulting their healthcare…
New online resources will help the public, parents, carers and health, social care and education professionals understand what safe, effective digital mental health technologies look like in practice.
Dstl/DMS competition through UKDI offers funding to innovators that can remedy gaps in modelling and treating conflict wounds
The Access Consortium — comprising regulatory authorities from the UK, Australia, Canada, Singapore and Switzerland — works together to streamline regulatory processes, support innovation and improve global public health out…
Nearly 20 million doses of potentially dangerous medicines prevented from reaching the public
People living in rural and coastal areas will find it easier to see a cancer specialist as the government works to end the postcode lottery for care.
The updated safety measures will strengthen the MHRA’s ability to monitor safe prescribing while supporting patient access to treatment across all age groups.
Study confirms vaccine being used in global efforts to achieve and sustain polio eradication is successfully interrupting polio outbreaks whilst minimising risk of new vaccine-derived outbreaks in Uganda
Paracetamol should be taken as directed in the patient information leaflet.
The Medicines and Healthcare products Regulatory Agency (MHRA) approved a maximum dose of up to 7.2mg per week of semaglutide (Wegovy) on 6 January 2026.
The MHRA is now setting out the next phase of reforms for 2026, aimed at helping patients access new cutting-edge treatments more quickly and boosting the UK’s competitiveness for global clinical research.
Updated product information and packaging will help patients better understand the risks of dependency, addiction, and withdrawal with these medicines.
As medicines and medical technologies become more complex, there are exciting opportunities to further strengthen our safety monitoring systems.
As with any medicine, the MHRA will keep the safety and effectiveness of Nirogacestat hydrobromide under close review.
In this new role, Professor George will lead the Agency’s science strategy and will oversee the MHRA’s scientific, research and innovation activities.
As with any medicine, the MHRA will keep the safety and effectiveness of zapomeran under close review.
As many people consider lifestyle changes at the start of the year, the Medicines and Healthcare products Regulatory Agency (MHRA) is urging the public to make sure any weight-loss medicines they use are safe, effective and …
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab and requires JavaScript).